IDM Pharma said founder, president and CEO Jean-Loup Romet-Lemonne is leaving to "pursue other opportunities." The board named Timothy Walbert, the former EVP of commercial operations at NeoPharm, to the CEO's job.
"Our immediate priority will be continuing to work with the regulatory authorities in the U.S. and Europe to complete the review process of Junovan," says Walbert. "Based on the Phase III results of the trial with Junovan, we are committed to an ongoing dialogue with the FDA and EMEA and believe that Junovan has the potential to be an important treatment for children with osteosarcoma."
- here's the release on the executive shuffle